Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Return on Invested Capital (2023 - 2024)

Foghorn Therapeutics has reported Return on Invested Capital over the past 2 years, most recently at 5.0% for Q3 2024.

  • Quarterly results put Return on Invested Capital at 5.0% for Q3 2024, up 281.0% from a year ago — trailing twelve months through Sep 2024 was 5.0% (up 281.0% YoY), and the annual figure for FY2023 was 2.93%, changed.
  • Return on Invested Capital for Q3 2024 was 5.0% at Foghorn Therapeutics, up from 1.8% in the prior quarter.
  • Over the last five years, Return on Invested Capital for FHTX hit a ceiling of 10.07% in Q1 2023 and a floor of 1.23% in Q1 2024.